🔍

Auro Laboratories Ltd (530233)

📊 BSE: 530233 🏢 Pharmaceuticals 📢 Latest filing: 14 Aug 2026 📝 Analysis written: 13 Nov 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Auro Laboratories' revenue was ₹8.8 Cr (+216.5% year on year, -10.8% on the previous quarter), and net profit ₹1.0 Cr (against a loss a year earlier); the operating margin was 37.7%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹8.8	+216.5%	-10.8%
Operating profit	₹3.3	—	-0.8%
Net profit	₹1.0	from loss	+7.8%
EPS (₹)	1.68	from loss	+7.7%
Operating margin	37.7%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Q1 Net Profit Jumps to ₹1.05 Cr vs Loss YoY; Revenue Up 216% YoY to ₹8.77 Cr

🟢 POSITIVE ⭐ 6/10

EARNINGS 📅 14 Aug 2026, 07:12 PM

Auro Laboratories reported revenue from operations of ₹8.77 Cr (₹876.81 Lakhs) for Q1 ended June 30, 2026, marking a 216% YoY surge compared to ₹2.77 Cr in Q1 FY26, though down 10.8% QoQ from ₹9.83 Cr. Net profit stood at ₹1.05 Cr (₹104.56 Lakhs), turning around from a net loss of ₹0.11 Cr in the prior-year quarter and up 7.7% QoQ from ₹0.97 Cr in Q4 FY26. Diluted EPS improved to ₹1.68 compared to negative ₹0.17 in Q1 FY26 and ₹1.56 in Q4 FY26. Operating performance reflects sustained revenue momentum above recent run-rates, with profitability remaining resilient despite raw material costs of ₹4.13 Cr.

Revenue from operations rose 216% YoY to ₹876.81 Lakhs vs ₹277.42 Lakhs in Q1 FY26
Net profit turned around to ₹104.56 Lakhs compared to a net loss of ₹10.55 Lakhs in Q1 FY26
Profit before tax stood at ₹113.05 Lakhs against a loss before tax of ₹10.55 Lakhs in Q1 FY26
Basic and diluted EPS stood at ₹1.68 for the quarter vs negative ₹0.17 in Q1 FY26
Total expenses were ₹774.59 Lakhs, driven by cost of raw materials of ₹412.66 Lakhs

💡 Track whether the company can sustain quarterly revenues in the ₹9-10 Cr band in upcoming quarters and monitor margin sustainability against raw material cost trends.

Q1 Net Profit at ₹1.05 Cr (vs Loss YoY); Revenue jumps 216% YoY to ₹8.77 Cr

🟢 POSITIVE ⭐ 6/10

EARNINGS 📅 14 Aug 2026, 07:03 PM

Auro Laboratories reported a net profit of ₹1.05 crore (₹104.56 lakhs) for the quarter ended June 30, 2026, turning around from a net loss of ₹0.11 crore (₹10.55 lakhs) in the corresponding year-ago quarter. Revenue from operations increased 216.1% YoY to ₹8.77 crore (₹876.81 lakhs), though it declined 10.8% sequentially from ₹9.83 crore in Q4 FY26. Diluted EPS stood at ₹1.68 for the quarter, compared to negative ₹0.17 YoY and ₹1.56 in Q4 FY26. Profit before tax reached ₹1.13 crore, despite elevated finance costs of ₹1.37 crore.

Revenue from operations grew 216.1% YoY to ₹876.81 lakhs compared to ₹277.42 lakhs in Q1 FY26
Net profit turned positive at ₹104.56 lakhs versus a loss of ₹10.55 lakhs in the year-ago period
EPS stood at ₹1.68 for the quarter, up from ₹(0.17) YoY and ₹1.56 in Q4 FY26
Finance costs remained elevated at ₹136.85 lakhs compared to ₹28.07 lakhs in Q1 FY26

💡 Track whether quarterly revenue sustains in the ₹9-10 crore range and whether high debt-servicing costs (₹1.37 cr finance cost this quarter) moderate in upcoming quarters.

Auro Laboratories Board Meeting on August 14, 2026, to Approve Q1 FY27 Results

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 10 Aug 2026, 07:03 PM

Auro Laboratories has scheduled a board meeting for August 14, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company is coming off a strong FY26 where annual revenue grew 58% to Rs 30.74 Cr compared to Rs 19.4 Cr in FY25. Investors will be monitoring if the company can sustain its high operating profit margin of 31.7% (TTM) and manage its relatively high debt-to-equity ratio of 1.37. The trading window for designated persons remains closed until 48 hours after the results are announced.

Board meeting scheduled for August 14, 2026, to approve Q1 FY27 results
Trading window has been closed since June 26, 2026, per internal code of conduct
Company reported a TTM revenue of Rs 31 Cr against a market cap of Rs 146 Cr
Operating profit margin stands at a healthy 31.7% as per latest TTM data

💡 Monitor the financial results on August 14 to evaluate if the revenue growth momentum from FY26 is sustained and how the company is managing its Rs 63 Cr debt load.

Auro Laboratories to Hold 37th AGM on August 11, 2026; FY26 Annual Report Link Shared

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 16 Jul 2026, 06:45 PM

Auro Laboratories has scheduled its 37th Annual General Meeting (AGM) for August 11, 2026, at 11:30 a.m. via video conferencing. The company is dispatching physical letters to shareholders who have not registered their email addresses, providing them with the web link to access the FY 2025-26 Annual Report. The cut-off date for identifying these shareholders was July 10, 2026. Additionally, the company reminded shareholders to update KYC details to ensure eligibility for electronic payments like dividends, as mandated by SEBI since April 01, 2024.

37th Annual General Meeting scheduled for August 11, 2026, at 11:30 a.m.
Cut-off date for shareholder communication was Friday, July 10, 2026.
Electronic payment mandate for dividends/interest effective since April 01, 2024.
KYC update reminder issued as per SEBI circular dated May 07, 2024.

💡 Shareholders should access the Annual Report via the company's website to review FY26 financial performance and operational updates ahead of the AGM.

Auro Laboratories Ltd Schedules 37th AGM for Aug 11, 2026; Releases FY26 Annual Report

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 16 Jul 2026, 06:34 PM

Auro Laboratories has released its Annual Report for FY 2025-26 and scheduled its 37th Annual General Meeting (AGM) for August 11, 2026. Key agenda items include the re-appointment of Mr. Kiran Kulkarni as Whole-Time Director for a three-year term starting May 2027. The company also confirmed management changes, including the appointment of Mr. Nitesh Bohra as CFO effective May 29, 2026. Shareholders will also vote on the ratification of ₹60,000 in remuneration for cost auditors for the upcoming fiscal year.

37th Annual General Meeting scheduled for August 11, 2026, at 11:30 AM via Video Conferencing.
Proposed re-appointment of Mr. Kiran Suresh Kulkarni as Whole-Time Director for a 3-year term effective May 24, 2027.
Ratification of ₹60,000 remuneration plus taxes for Cost Auditors M/s. Poddar & Co. for FY 2026-27.
Management transition noted with Mr. Nitesh Bohra appointed as CFO effective May 29, 2026.
Company Secretary transition completed with CS Padma Tapariya taking over from October 01, 2025.

💡 Investors should review the 'Management Discussion and Analysis' section within the full Annual Report for insights into the company's operational performance and future outlook.

Auro Laboratories Schedules 37th AGM for Aug 11, 2026; WTD Re-appointment Proposed

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 16 Jul 2026, 06:22 PM

Auro Laboratories has convened its 37th Annual General Meeting (AGM) for August 11, 2026, to adopt the FY 2025-26 financial results. A key agenda item is the re-appointment of Mr. Kiran Suresh Kulkarni as Whole-Time Director for a three-year term starting May 24, 2027. The company is seeking shareholder approval via a special resolution to pay managerial remuneration potentially exceeding regulatory limits in the event of inadequate profits. Additionally, the board has proposed ratifying a cost audit fee of ₹60,000 for FY 2026-27.

37th Annual General Meeting scheduled for August 11, 2026, at 11:30 AM via Video Conferencing.
Proposal to re-appoint Mr. Kiran Suresh Kulkarni as Whole-Time Director for a 3-year term effective May 24, 2027.
Ratification of ₹60,000 plus taxes as remuneration for Cost Auditors M/s. Poddar & Co. for FY 2026-27.
Management transitions confirmed: Mr. Nitesh Bohra appointed as CFO effective May 29, 2026.
CS Padma Tapariya appointed as Company Secretary and Compliance Officer effective October 01, 2025.

💡 Investors should monitor the voting results of the special resolution regarding director remuneration, particularly the provision for payment in case of inadequate profits, and review the full FY26 annual report for operational performance details.

View All 530233 Announcements on Live Market Tracking →